Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections

4 Mar 2009

Abstract excerpt

OBJECTIVES: The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection. METHODS: The spectrum of activity of REP3123 was determined by susceptibility testing of C. difficile and non-target organisms. The mode of action was studied by enzyme inhibition assays,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Clostridium difficile and Clostridium perfringens research
Share to Enzyme Structure and Function

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19258353
DOI: 10.1093/jac/dkp041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infectionsPMID 19258353Read ↗

Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity.Semantic proximity Read ↗

OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infectionsSemantic proximity Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.Semantic proximity Read ↗

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infectionSemantic proximity Read ↗

<i>In vitro</i> efficacy of synthetic antimicrobial peptide SET-M33 against poultry isolates with diverse antimicrobial resistance phenotypesSemantic proximity Read ↗

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.Semantic proximity Read ↗

Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa.Semantic proximity Read ↗

Multispecies activity screening of microcin J25 mutants yields antimicrobials with increased specificity toward pathogenic Salmonella species relative to human commensal Escherichia coli.Semantic proximity Read ↗

Elucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosa.Semantic proximity Read ↗

Flexible cobamide metabolism in <i>Clostridioides (Clostridium) difficile</i> 630 Δ <i>erm</i>Semantic proximity Read ↗

Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial InfectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.